Physician profile
Arika Gupta
NPI 1831171735
$5,688.85
in general payments reported to CMS, 2019-2025
27 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $459 · 2021: $662 · 2022: $664 · 2023: $614 · 2024: $1,561 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,335 · Education: $32.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,335.10 |
| Education | $32.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $806.89 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $719.89 | 2019-2025 | Krystexxa, Tavneos, Aranesp |
| Calliditas Therapeutics US INC. | $710.68 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $591.00 | 2019-2025 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $376.19 | 2022-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $366.38 | 2019-2023 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $320.58 | 2021-2025 | |
| Travere Therapeutics, INC. | $284.92 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.86 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $167.47 | 2020-2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $142.31 | 2025 | |
| Ardelyx, INC. | $137.61 | 2024-2025 | Ibsrela |
| Vifor Pharma, INC. | $129.96 | 2020-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $117.09 | 2022-2023 | Acthar |
| Scpharmaceuticals INC. | $86.97 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $84.67 | 2024 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $84.66 | 2024 | Velphoro |
| Akebia Therapeutics INC | $70.06 | 2019-2021 | |
| Horizon Therapeutics Plc | $48.27 | 2021-2022 | |
| Abiomed | $27.16 | 2025 | |
| Tactile Systems Technology INC | $24.96 | 2025 | Flexitouch Plus, Nimbl |
| Regeneron Healthcare Solutions, INC. | $24.14 | 2025 | Dupixent |
| Kyowa Kirin, INC. | $20.27 | 2023 | Crysvita |
| Daiichi Sankyo INC. | $19.32 | 2024 | Injectafer |
| Alexion Pharmaceuticals, INC. | $16.42 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $13.94 | 2019 | |
| Merck Sharp & Dohme LLC | $13.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arika Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.